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Gene therapyepidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling
negatively affects intracellular trafﬁcking and transduction efﬁciency of recombinant adeno-associated virus
2 (AAV2) vectors. Speciﬁcally, inhibition of EGFR-PTK signaling leads to decreased ubiquitination of AAV2
capsid proteins, which in turn, facilitates viral nuclear transport by limiting proteasome-mediated
degradation of AAV2 vectors. In the present studies, we observed that AAV capsids can indeed be
phosphorylated at tyrosine residues by EGFR-PTK in in vitro phosphorylation assays and that phosphorylated
AAV capsids retain their structural integrity. However, although phosphorylated AAV vectors enter cells as
efﬁciently as their unphosphorylated counterparts, their transduction efﬁciency is signiﬁcantly reduced. This
reduction is not due to impaired viral second-strand DNA synthesis since transduction efﬁciency of both
single-stranded AAV (ssAAV) and self-complementary AAV (scAAV) vectors is decreased by ∼68% and ∼74%,
respectively. We also observed that intracellular trafﬁcking of tyrosine-phosphorylated AAV vectors from
cytoplasm to nucleus is signiﬁcantly decreased, which results from ubiquitination of AAV capsids followed by
proteasome-mediated degradation, although downstream consequences of capsid ubiquitination may also be
affected by tyrosine-phosphorylation. These studies provide new insights into the role of tyrosine-
phosphorylation of AAV capsids in various steps in the virus life cycle, which has implications in the optimal
use of recombinant AAV vectors in human gene therapy.
© 2008 Elsevier Inc. All rights reserved.Introduction
Recombinant adeno-associated virus 2 (AAV2) vectors have gained
attention as an alternative to themore commonly used retrovirus- and
adenovirus-based vectors for gene transfer and gene therapy (Berns
andGiraud,1996;Muzyczka,1992). A number of Phase I/II clinical trials
have been initiated, or are currently underway, that utilize recombi-
nant AAV2 vectors for the potential gene therapy of human diseases
such as cystic ﬁbrosis, α-1 anti-trypsin deﬁciency, Parkinson's disease,olecular Therapy, Cancer and
492-A, University of Florida
352 273 8342.
l rights reserved.Batten's disease, andmuscular dystrophy (Flotte et al., 1996, 2004; Kay
et al., 2000; Snyder and Francis, 2005). RecombinantAAV2vectors have
also been reported to transduce a wide variety of cells and tissues in
vitro and in vivo (Flotte et al.,1993;Muzyczka,1992; Snyder et al.,1997;
Xiao, Li, and Samulski,1996). Several fundamental steps in the life cycle
of AAV2 vectors, such as viral binding and entry (Kashiwakura et al.,
2005; Qing et al., 1999; Summerford et al., 1999; Summerford and
Samulski, 1998), intracellular trafﬁcking (Douar et al., 2001; Hansen et
al., 2000, 2001; Sanlioglu et al., 2000; Zhao et al., 2006), uncoating
(Thomas et al., 2004; Zhong et al., 2004c), second-strand DNA
synthesis and transgene expression (Ferrari et al., 1996; Fisher et al.,
1996; Qing et al., 1997; Zhong et al., 2004a, 2004b, 2004d, 2008b), and
viral genome integration into host cell chromosome (McCarty, Young,
and Samulski, 2004; Tan et al., 2001; Zhong et al., 2006), have been
studied extensively.
Fig. 1. Autoradiographic image of SDS-polyacrylamide gel for in vitro phosphorylation
of AAV2 capsids by CKII and EGFR-PTK. Approximately 4.8×1010 particles of intact (I)
and denatured (D) ssAAV2-adiponectin (K9) vectors were incubated in the absence of
a protein kinase (lanes 1 and 2). CKII was incubated in the absence (lane 3) or
presence of intact (I) (lane 4) or denatured (D) (lane 5) K9 vectors. Similarly, EGFR-PTK
was incubated in the absence (lane 6) or presence of intact (I) (lane 7) or denatured
(D) (lane 8) K9 vectors as described under Materials and methods. The arrows indicate
the phosphorylated forms of AAV2 capsid proteins, and the closed and open
arrowheads denote the autophosphorylated CKII and EGFR-PTK, respectively. These
results are representative of two independent experiments.
195L. Zhong et al. / Virology 381 (2008) 194–202Previous studies have shown that the ubiquitin–proteasome
pathway plays a critical role in intracellular trafﬁcking of AAV2
vectors (Ding et al., 2005, 2006; Douar et al., 2001; Duan et al., 2000).
We recently reported that perturbations in EGFR-PTK signaling affects
AAV2 transduction efﬁciency by not only augmenting viral second-
strand DNA synthesis, but also by facilitating intracellular trafﬁckingFig. 2. (A) Western blot analyses of in vitro phosphorylation of AAV2 capsids by EGFR-PTK f
were incubated in the absence of EGFR-PTK (lanes 3, 5, and 7) and EGFR-PTKwas mock-incub
and 8) as described under Materials and methods. The reaction samples were analyzed by W
capsid proteins. The arrows indicate the phosphorylated forms of AAV2 capsid proteins, and
(baculovirus-based AAV2 packaging system); RFP: ssAAV2-RFP (293 cells-based AAV2 pack
These results are representative of two independent experiments. (B) Western blot analyses o
virions and free capsid proteins. Approximately 3×1010 particles of AAV2 vectors were incu
(lane 1) or presence of AAV2 vectors (lane 3) followed by separation of N100 kDa fraction (in
and 9) using centrifugal ﬁlter devices [(Ultracel YM-100 (KD) and YM-30 (KD)] as described u
p-Tyr antibody for detection of phospho-tyrosine containing capsid proteins (upper panel) a
arrows indicate the phosphorylated and total AAV2 capsid proteins, and the open arrowheafrom the cytoplasm to nucleus (Zhong et al., 2007). These studies led
to the hypothesis that prior to exiting the late endosomes, intact AAV2
particles become phosphorylated at tyrosine residues by EGFR-PTK,
which leads to ubiquitination and subsequent degradation of a
substantial fraction of the vectors by the cytoplasmic proteasomes,
which negatively impacts the efﬁciency of their transport to the
nucleus.
We report here that intact AAV2 capsids can be phosphorylated at
tyrosine residues by EGFR-PTK, but not at serine/threonine residues by
casein kinase II (CKII), under cell-free conditions in vitro. We also
document that tyrosine-phosphorylation of AAV2 capsids negatively
affects the viral intracellular trafﬁcking and transgene expression in
intact cells in vivo. These studies provide new insights into the role of
tyrosine-phosphorylation of AAV2 capsid in various steps in the life
cycle of AAV2, which have implications in the optimal use of
recombinant AAV2 vectors in human gene therapy.
Results
Intact AAV2 capsids can be phosphorylated at tyrosine residues by
EGFR-PTK, but not at serine/threonine residues by CKII, in in vitro
phosphorylation assays
One of the predictions from our recently published model was that
AAV2 vectors become phosphorylated at tyrosine residues by EGFR-
PTK in the late endosome (Zhong et al., 2007). However, whether
intact AAV2 capsid proteins can be phosphorylated at tyrosine and/or
serine/threonine residues has not been reported. Using in vitro
phosphorylation assays, we ﬁrst examined whether intact or
denatured AAV2 capsid could be phosphorylated by casein kinase II
(CKII) or EGFR-PTK. As shown in Fig. 1, the results clearly indicate that
denatured AAV2 capsid proteins (lanes 5 and 8) can be readily
phosphorylated in vitro by CKII and EGFR-PTK at serine/threonine and
tyrosine residues, respectively. However, intact AAV2 capsids could
not be phosphorylated by CKII (lane 4), but phosphorylation atrom two different packaging systems. Approximately 3×1010 particles of AAV2 vectors
ated (lane 1) or incubated in the absence (lane 2) or presence of AAV2 vectors (lanes 4, 6,
estern blotting using anti-p-Tyr antibody for detection of phospho-tyrosine containing
the open arrowhead denotes the autophosphorylated EGFR-PTK. K9: AAV2-adiponectin
aging system); scEGFP: scAAV2-CBAp-EGFP (293 cell-based AAV2 packaging system).
f in vitro phosphorylation of AAV2 capsids by EGFR-PTK followed by separation of intact
bated in the absence of EGFR-PTK (lane 2) and EGFR-PTK was incubated in the absence
tact virions) (lanes 4, 5, and 6) and 30–100 kDa fraction (free capsid proteins) (lane 7, 8,
nder Materials andmethods. The samples were analyzed byWestern blotting using anti-
nd anti-AAV2 cap (B1) antibody for detection of total capsid proteins (lower panel). The
d denotes the autophosphorylated EGFR-PTK.
Fig. 3. DNA slot blot analysis for AAV2 entry into HeLa cells after in vitro phosphorylation
of AAV2 capsids by EGFR-PTK. HeLa cells were mock-infected (lane 1) or infected with
AAV2-lacZ vectors, which were either mock-incubated (lane 2) or pre-incubated with
ATP (lane 3), EGFR-TPK (lane 4) or both (lane 5). Following digestion with trypsin to
degrade adsorbed and unadsorbed vectors, low-Mr DNA samples were isolated 2 h
post-infection and analyzed on by slot blot hybridization using a 32P-labeled lacZ DNA
probe.
196 L. Zhong et al. / Virology 381 (2008) 194–202tyrosine residues by EGFR-PTK was readily observed (lane 7).
Tyrosine-phosphorylation of AAV2 capsids by EGFR-PTK occurred
regardless of the vector production method or the encapsidated
transgene. For example, Western blot analyses using anti-phospho-
tyrosine (anti-p-Tyr) antibody revealed that phospho-tyrosines could
not be detected in single-stranded AAV2 (ssAAV2) vectors containing
the canine adiponectin gene (K9) produced by the baculovirus-based
packaging system, or ssAAV2 vectors containing the red ﬂuorescence
protein (RFP), or self-complementary AAV2 (scAAV2) vectors contain-
ing the enhanced green ﬂuorescent protein (EGFP) gene generated by
the 293 cell-based packaging system (Fig. 2A, lanes 3, 5, and 7).
However, all vector preparations could be phosphorylated by EGFR-
PTK (Fig. 2A, lanes 4, 6, and 8). We also examined whether in vitro
phosphorylation conditions per se lead to vector instability. To this
end, following in vitro phosphorylation of AAV2 capsids by EGFR-PTK,
intact virions (N100 kDa) were separated from free capsid proteins
(30–100 kDa) using centrifugal ﬁlter devices [(Ultracel YM-100 (KD)
and YM-30 (KD)] and analyzed on Western blots using anti-p-Tyr
antibody for detection of phospho-tyrosine containing capsid proteins
as well as anti-AAV2 capsid (B1) antibody for detection of total capsid
proteins. As shown in Fig. 2B, both the tyrosine-phosphorylated
(upper panel) and AAV2 capsid proteins (lower panel) were detected
in the N100 kDa fraction (lanes 5 and 6). No signals were detected in
the 30–100 kDa fraction (lanes 8 and 9). We conclude, therefore, that
tyrosine-phosphorylated AAV2 vectors retain their structural
integrity.
Tyrosine-phosphorylated AAV2 vectors are infectious, but their
transduction efﬁciency is signiﬁcantly reduced
We next evaluated whether tyrosine-phosphorylation affected
the biological activity of AAV2 vectors by examining their ability to
bind and enter the target cell as well as their ability to express the
encapsidated transgene. For the ﬁrst set of experiments, recombi-
nant AAV2-lacZ vectors were pre-incubated with ATP alone, EGFR-
PTK alone, or ATP+EGFR-PTK, and used to infect HeLa cells at 37 °CFig. 4. (A) Comparative analyses of AAV2-mediated transduction efﬁciency in HeLa cells af
ssAAV2-RFP vectors, which were pre-incubated with ATP, EGFR-TPK, or both. Transgene
magniﬁcation 100×. (B) Quantitative analyses of AAV2 transduction efﬁciency in HeLa cells.
Transgene expression was assessed as total area of red ﬂuorescence (pixel2) per visual ﬁeld
control and they were determined to be statistically signiﬁcant. ⁎Pb0.05 vs. ssAAV2-RFP. (C)
both. Transgene expression was detected by ﬂuorescence microscopy at 48 h post-infection
was assessed as described above, and were determined to be statistically signiﬁcant. ⁎Pb0.05
HeLa cells after in vitro phosphorylation of AAV2 capsids by CKII. HeLa cells were infected
expression was detected by ﬂuorescence microscopy 48 h post-infection. Original magniﬁc
described above. (G) Infection of HeLa cells with scAAV2-EGFP vectors pre-incubated with A
post-infection. Original magniﬁcation 100×. (H) Quantitative analyses of AAV2 transductionfor 2 h under identical conditions. Following exhaustive digestion
with trypsin to remove any free virions, low-Mr DNA samples were
isolated at 2 h post-infection and analyzed on DNA slot-blots using a
32P-labeled lacZ DNA probe. As can be seen in Fig. 3, in vitro
phosphorylation of AAV2 capsids by EGFR-PTK had no effect on viral
binding and entry into HeLa cells.
For the second set of experiments, both ssAAV2 and scAAV2
vectors were used since tyrosine-phosphorylation negatively affects
viral second-strand DNA synthesis of ssAAV2 vectors (Mah et al., 1998;
Qing et al., 2001,1997; Zhong et al., 2004a, 2004b, 2004d), and scAAV2
vectors bypass the requirement for viral second-strand DNA synthesis
(McCarty et al., 2003; Wang et al., 2003). HeLa cells were mock-
infected or infected with ssAAV2-RFP or scAAV2-EGFP vectors, which
were either mock-treated or incubated with ATP alone, EGFR-PTK
alone, or ATP+EGFR-PTK, as described above. Transgene expression
was detected by ﬂuorescence microscopy 48 h post-infection. As is
evident from the results shown in Fig. 4, in vitro phosphorylation of
viral capsids by EGFR-PTK decreased transgene expression by ∼68%
for ssAAV2 vectors (panels A, B) and by ∼74% for scAAV2 vectors
(panels C, D). Treatment of viral capsids with CKII, on the other hand,
had no effect on either ssAAV2 vectors (panels A, B) or scAAV2 vectors
(panels C, D). Thus, we conclude that although tyrosine-phosphory-
lated AAV2 vectors enter cells as efﬁciently as their unphosphorylated
counterparts, their transduction efﬁciency is signiﬁcantly reduced.
This reduction is not due to impaired viral second-strand DNA
synthesis since transduction efﬁciency of both ssAAV2 and scAAV2
vectors is affected.
AAV2 capsids are phosphorylated at tyrosine residues following infection,
and in vitro phosphorylation of viral capsids at tyrosine residues leads to
ubiquitination of intact AAV2 vectors
Since AAV2 vectors could be phosphorylated by EGFR-PTK in vitro,
we also wished to evaluate whether intact AAV2 particles also
undergo tyrosine-phosphorylation following infection. This was
carried out as follows. HeLa cells were either mock-treated or treated
with sodium orthovanadate (NaOV), a speciﬁc inhibitor of protein
phosphatases, and then were either mock-infected or infected with
AAV2 vectors for 2 h at 37 °C.Whole cell lysates (WCLs) were prepared
4 h post-infection and equivalent amounts of proteins were immuno-
precipitated ﬁrst with anti-AAV2 capsid antibody (A20) followed by
Western blot analyses using anti-p-Tyr antibody. These results are
shown in Fig. 5A. As can be seen, tyrosine-phosphorylated AAV2
capsid proteins (P-Tyr-AAV2 Cap) were readily detectable in AAV2-
infected cells (lanes 1 and 2). No signal was detectable in mock-
infected cells (lane 3), and the extent of tyrosine-phosphorylation of
AAV2 capsid proteins was increased following treatment with NaOV
(lane 2). These results suggest that AAV2 vectors are indeed
phosphorylated at tyrosine residues following infection of cells.
We next examined why tyrosine-phosphorylated AAV2 vectors
failed to efﬁciently transduce the target cell. The ubiquitin–protea-
some pathway plays an important role in the cell by speciﬁcally
degrading both endogenous and foreign proteins (Pickart, 2001;
Schwartz and Ciechanover,1999). Direct evidence for ubiquitination of
AAV2 capsid proteins in HeLa cells and in in vitro ubiquitination assayster in vitro phosphorylation of AAV2 capsids by EGFR-PTK. HeLa cells were infected by
expression was detected by ﬂuorescence microscopy 48 h post-infection. Original
Images from ﬁve visual ﬁelds were analyzed quantitatively by ImageJ analysis software.
(mean±SD). Analysis of variance (ANOVA) was used to compare test results with the
Infection of HeLa cells with scAAV2-EGFP vectors pre-incubated with ATP, EGFR-TPK, or
. Original magniﬁcation 100×. (D) Quantitative analyses of AAV2 transduction efﬁciency
vs. scAAV2-EGFP. (E) Comparative analyses of AAV2-mediated transduction efﬁciency in
by ssAAV2-RFP vectors, which were pre-incubated with ATP, CKII, or both. Transgene
ation 100×. (F) Quantitative analyses of AAV2 transduction efﬁciency was assessed as
TP, CKII, or both. Transgene expression was detected by ﬂuorescence microscopy 48 h
efﬁciency were assessed as described above.
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Fig. 5. (A) Detection of intracellular tyrosine-phosphorylation of intact AAV2 vectors. Whole cell lysates (WCLs) prepared from HeLa cells untreated (lanes 1 and 3) or treated with
NaOV (lane 2) following infection with K9 vectors (lanes 1 and 2) or mock-infection (lane 3), were immuno-precipitated with anti-AAV2 capsid antibody A20 followed by Western
blot analyses with anti-p-Tyr antibody. (B) Detection of intracellular ubiquitin-conjugation of intact AAV2 vectors after in vitro phosphorylation of viral capsids by EGFR-PTK.Western
blot analyses of ubiquitinated AAV2 capsid proteins in HeLa cells following transduction with ssAAV2-K9 vectors after in vitro phosphorylation of viral capsids by EGFR-PTK. Whole
cell lysates (WCLs) prepared from HeLa cells untreated or treated with MG132 following mock-infected (lanes 1 and 2), or infected with K9 vectors, which were mock-incubated
(lanes 3 and 4), or incubated with ATP (lanes 7 and 8), EGFR-PTK (lanes 9 and 10) or both (lanes 5 and 6), were immuno-precipitated with anti-AAV2 capsid antibody A20 followed by
Western blot analyses with anti-Ub monoclonal antibody P4D1. This result is representative of two independent experiments.
198 L. Zhong et al. / Virology 381 (2008) 194–202has been reported (Yan et al., 2002), where only denatured AAV2
capsids, but not intact AAV2, could be ubiquitinated in vitro, which
suggested that either a conformational change or a modiﬁcation, such
as phosphorylation of intact AAV2 capsid is required before ubiqui-
tination can ensue. A number of studies have reported that
phosphorylation of cellular proteins at tyrosine or serine/threonine
residues is required for efﬁcient ubiquitination and degradation of
these proteins (Brown et al., 1995; Cenciarelli et al., 1996; Paolini et al.,
1999; Penrose et al., 2004).
Since in our previously published studies (Zhong et al., 2007), we
reported that inhibition of EGFR-PTK signaling decreases ubiquitina-
tion of total cellular proteins as well as AAV2 capsid proteins, we
examined whether in vitro phosphorylation of viral capsids by EGFR-
PTK leads to ubiquitination of AAV2 capsids in intact cells. This was
carried out as follows. HeLa cells were either mock-treated or treated
with MG132, a speciﬁc inhibitor of proteasomes, and thenwere either
mock-infected or infected with AAV2 vectors, with and without
tyrosine-phosphorylation, for 2 h at 37 °C. Whole cell lysates (WCLs)
were prepared 4 h post-infection and equivalent amounts of proteins
were immuno-precipitated ﬁrst with anti-AAV2 capsid antibody (A20)
followed by Western blot analyses using anti-Ub monoclonal anti-
body. These results are shown in Fig. 5B. As can be seen, the
ubiquitinated AAV2 capsid proteins (Ub-AAV2 Cap) were undetectable
inmock-infected cells (lanes 1 and 2), the signal of ubiquitinated AAV2
capsid proteins was weaker in untreated cells (lanes 3, 5, 7, and 9), but
a signiﬁcant accumulation of ubiquitinated AAV2 capsid proteins
occurred following treatment with MG132 (lanes 4, 6, 8, and 10). Most
interestingly, in vitro phosphorylation of viral capsids by EGFR-PTK
dramatically increased the extent of accumulation of MG132-induced
ubiquitinated AAV2 capsid proteins (lane 6). These results strongly
suggest that in vitro phosphorylation of capsids by EGFR-PTK leads to
ubiquitination of AAV2 capsids in intact cells. However, since MG132
potentiates capsid ubiquitination as well as increases transduction, it
is also possible that capsid ubiquitination serves as a positive sorting
signal and not as a negative degradation signal. Thus, tyrosine-
phosphorylation of AAV2 capsids may limit transduction by affecting
other events during infection.In vitro phosphorylation of viral capsids at tyrosine residues leads to
impaired intracellular trafﬁcking to the nucleus
The ubiquitin–proteasome pathway plays a critical role in AAV2
intracellular trafﬁcking, and proteasome inhibitors can promote
AAV2 nuclear transport, leading to augmentation of AAV2 transduc-
tion (Ding et al., 2005, 2006; Douar et al., 2001; Duan et al., 2000).
We have also documented that inhibition of EGFR-PTK signaling
facilitates nuclear transport of AAV2 vectors (Zhong et al., 2004c,
2007), which suggested that phosphorylation of AAV2 capsids by
EGFR-PTK might also be involved in AAV2 trafﬁcking. To further
examine this hypothesis, we examined the cytoplasmic and nuclear
distribution of AAV2 genomes following in vitro phosphorylation of
AAV2 vectors. HeLa cells were infected with AAV2-lacZ vectors,
with or without tyrosine-phosphorylation, as described above.
Nuclear and cytoplasmic fractions were obtained 18 h post-
infection, and low-Mr DNA samples were isolated and analyzed
on Southern blots using a 32P-labeled lacZ DNA probe. These results
are shown in Fig. 6, panel A. A signiﬁcant fraction of the input
ssAAV2 DNA was present in the cytoplasm following infection with
AAV2 vectors that were mock-treated or pre-incubated with ATP
alone, or with EGFR-TPK alone (lanes 2, 3, and 4), and only a small
fraction was detected in the nucleus (lanes 7, 8, and 9).
Interestingly, however, in cells infected with AAV2 vectors that
were phosphorylated by EGFR-PTK, the input ssAAV2 DNA in the
cytoplasmic fraction was increased (lane 5) with a corresponding
decrease in the nuclear fraction (lane 10). Densitometric scanning
of autoradiographs (Fig. 6, panel B) indicated that ∼35% of the
input ssAAV2 DNA was present in the nuclear fraction in cells
infected with AAV2 vectors in the absence of tyrosine-phosphor-
ylation, but only ∼16% following in vitro phosphorylation at
tyrosine residues. These data are consistent with our previous
studies (Zhong et al., 2007), and corroborate that intracellular
trafﬁcking of tyrosine-phosphorylated AAV2 vectors from the
cytoplasm to the nucleus is signiﬁcantly decreased, which is due
most likely to increased ubiquitination of AAV2 capsids followed by
proteasome-mediated degradation.
199L. Zhong et al. / Virology 381 (2008) 194–202Discussion
Our original observation that speciﬁc inhibitors of cellular protein
tyrosine kinases in general, and EGFR-PTK in particular, but not
inhibitors of cellular serine/threonine kinases, dramatically increase
the transduction efﬁciency of ssAAV vectors (Mah et al., 1998; Qing
et al., 1997), prompted us to pursue a series of studies in which we
identiﬁed that a cellular chaperone protein, FKBP52, is phosphory-
lated at tyrosine residues by EGFR-PTK, and that tyrosine-phos-
phorylated FKBP52 strongly inhibits the viral second-strand DNA
synthesis, and consequently the transgene expression (Qing et al.,
2001, 2003; Zhong et al., 2004a, 2004b, 2004d, 2008b). More
recently, however,we observed that in addition to negatively impacting
viral second-strand DNA synthesis and transgene expression in the
nucleus, EGFR-PTK-signaling also negatively regulates viral intracellu-
lar trafﬁcking in the cytoplasm (Zhong et al., 2007). Based on these
studies, we hypothesized that either prior to or during viral egress from
the late endosome, EGFR-PTK catalyzes the phosphorylation of intact
AAV2 capsids, which is a putative signal for ubiquitination. Ubiquiti-
nated AAV2 capsids are subsequently targeted for degradation by the
cellular proteasome. That intact AAV2 vectors can indeed be
phosphorylated at tyrosine residues by EGFR-PTK, both in vitro and in
vivo, but not at serine/threonine residues by CKII, as described in the
present studies, lends strong support to our hypothesis.
Although the Ub/proteasome pathway has previously been shown
to play an essential role in AAV2 nuclear transport (Ding et al., 2005,
2006; Douar et al., 2001; Duan et al., 2000), our data also provide
direct evidence that EGFR-PTK-mediated tyrosine-phosphorylation of
AAV2 capsids leads to ubiquitination, and subsequent degradation by
the proteasome, which impairs viral nuclear transport as well as
transduction efﬁciency of AAV2 vectors. Whether AAV2 vectors can be
phosphorylated at serine/threonine residues by other cellular serine/
threonine kinase(s), and what consequences, if any, of serine/
threonine phosphorylation of capsids have on the wild-type (WT)
AAV2 biology, remains unclear. What has become clear from our
current studies is that phosphorylation of the surface-exposed
tyrosine residues on recombinant AAV2 vector capsids is not desirable
since site-directed mutagenesis of these tyrosine residues resulted in
the generation of AAV2 vectors that are capable of transducing a wide
variety of cells and tissues in vitro and in vivo signiﬁcantly more
efﬁciently than those with the WT capsids (Zhong et al., 2008a).
Further studies on the precise role of tyrosine-phosphorylation of
AAV2 capsids are likely to lead not only to a better understanding ofFig. 6. Detection of intracellular trafﬁcking of AAV2 vectors to the nucleus after in vitro phos
nuclear distribution of AAV2 genomes in HeLa cells after in vitro phosphorylation of AAV2 caps
vectors, whichweremock-incubated (lanes 2 and 7) or pre-incubatedwithATP (lanes 3 and8),
prepared 18 h post-infection, low-Mr DNA sampleswere isolated and electrophoresed on 1% ag
probe. (B) Densitometric scanning of autoradiographs for the quantitation of relative amountvarious steps in the virus life cycle, but also to aid in the development
of novel recombinant AAV vectors especially in view of the fact that
the surface-exposed tyrosine residues are conserved in AAV serotypes
1 through 10, which has implications in the potential use of AAV
serotype vectors in human gene therapy.
Materials and methods
Cells, viruses, plasmids, antibodies, and chemicals
The human cervical carcinoma cell line, HeLa, was obtained from
the American Type Culture Collection (ATCC, Rockville, MD). The cell
line was maintained as monolayer cultures in Iscove's-modiﬁed
Dulbecco's medium (IMDM) supplemented with 10% newborn calf
serum (NCS) and 1% (by volume) of 100× stock solution of antibiotics
(10,000 U penicillin+10,000 μg streptomycin). Highly puriﬁed stocks
of ssAAV2 vectors containing the β-galactosidase (lacZ) reporter gene,
red ﬂuorescence protein (RFP) gene, or scAAV2 vectors containing the
enhanced green ﬂuorescence protein (EGFP) gene driven by the chick
β-actin (CBA) promoter (ssAAV2-lacZ, ssAAV2-RFP, or scAAV2-EGFP)
were generated as described previously (Auricchio et al., 2001).
ssAAV2 vectors containing the canine adiponectin gene (ssAAV2-K9)
were generated by a baculovirus-based packaging system as described
previously (Urabe et al., 2002). Physical particle titers of recombinant
vector stocks were determined by quantitative DNA slot blot
analysis. An AAV2-helper plasmid, pACG-2, containing the AAV2
rep gene with an ACG start codon, was generously provided by Dr. R.
Jude Samulski (University of North Carolina at Chapel Hill, Chapel
Hill, NC). A self-complementary AAV2 (scAAV2) cloning vector,
pdsCBA-EGFP, was a kind gift from Dr. Xiao Xiao (University of
North Carolina at Chapel Hill). Horseradish peroxidase (HRP)-
conjugated antibody speciﬁc for ubiquitin (Ub) (mouse monoclonal
immunoglobulin G1 [IgG1], clone P4D1), antibody speciﬁc for
phosphorylated tyrosine residues (anti-p-Tyr) (mouse monoclonal
IgG2b, clone PY99), HRP-conjugated goat anti-mouse IgG2b antibody,
HRP-conjugated goat anti-mouse IgG1 antibody, normal mouse IgG
and protein G plus-agarose were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibody speciﬁc for intact AAV2
particles (mouse monoclonal IgG3, clone A20) and antibody speciﬁc
for AAV2 capsid proteins (mouse monoclonal IgG1, clone B1) were
obtained from Research Diagnostics, Inc. (Flanders, NJ). MG132 was
purchased from Calbiochem (La Jolla, CA). All other chemicals were
purchased from Sigma-Aldrich Co. (St. Louis, MO).phorylation of viral capsids by EGFR-PTK. (A) Southern blot analyses of cytoplasmic and
ids by EGFR-PTK. HeLa cells were mock-infected (lanes 1 and 6) or infected by AAV2-lacZ
EGFR-TPK (lanes 4 and 9) or both (lanes 5 and10). Nuclear and cytoplasmic fractionswere
arose gels followed analyzed by Southern blot hybridization using a 32P-labeled lacZDNA
s of viral genomes. These results are representative of two independent experiments.
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In vitro phosphorylation by CKII (Calbiochem, La Jolla, CA) was
carried out as previously described (Qing et al., 2001; Zhong et al.,
2004d). Brieﬂy, the complete reaction mixture contained identical
amount of intact or denatured AAV2 vectors (∼3–4.8×1010 viral
particles), 20 mM Tris–HCl, 50 mM KCl, 10 mM MgCl2, 50 mM
Na3VO4, 10 μCi (0.37 mBq) γ-32P-ATP and 500 U (500,000 U/ml)
puriﬁed CKII. In vitro phosphorylation by EGFR-PTK was carried out
as described previously (Qing et al., 2001; Weber et al., 1984; Zhong
et al., 2004d), with the following modiﬁcations. The complete
reaction mixture contained identical amounts of intact or denatured
AAV2 vectors (∼3–4.8×1010 viral particles), 20 mM HEPES, 4 mM
MgCl2, 10 mM MnCl2, 10 μCi (0.37 mBq) γ-32P-ATP and 10 U
(15,000 U/mg) puriﬁed EGFR-PTK (Sigma-Aldrich Co., St. Louis, MO)
with the indicated appropriate controls. The reaction mixtures were
incubated at 30 °C for 1 h. The phosphorylated AAV2 capsid proteins
were separated from free γ-32P-ATP on 10% SDS-polyacrylamide gels
followed by autoradiography with Kodak 7 X-Omat ﬁlm at −70 °C. In
some experiments, in vitro phosphorylation assays by EGFR-PTK
were also carried out by adding 200 μM ATP instead of γ-32P-ATP.
The phosphorylated AAV2 capsid proteins were identiﬁed by
Western blotting with anti-p-Tyr antibody as described below.
Separation of intact AAV2 virions and AAV2 capsid proteins using
ultraﬁltration assay
After in vitro phosphorylation assays, the reaction samples plus
450 μl of phosphate buffered saline (PBS, pH7.4) were added into the
upper part of the YM-100 Microcon® centrifugal ﬁlter device (cutoff
value: 100 kDa) (Millipore Corporation, Bedford, MA) and centri-
fuged at 14,000 ×g for 24 min at 4 °C. Approximately 10–20 μl of
ultraﬁltrates was collected. The ﬂow through samples were added
into the upper part of the YM-30 Microcon® centrifugal ﬁlter device
(cutoff value: 30 kDa) (Millipore Corporation, Bedford, MA) and
centrifuged at 14,000 ×g for 24 min at 4 °C. Approximately 10–20 μl
of ultraﬁltrates was collected. The ultraﬁltrate samples were
analyzed by Western blotting using anti-p-Tyr and anti-AAV2 cap
(B1) antibodies as described below.
Preparation of whole cell lysates (WCLs) and co-immunoprecipitations
WCLs were prepared as described previously (Zhao et al., 2006;
Zhong et al., 2004d; Zhong and Su, 2002), with the following
modiﬁcations. Brieﬂy, 2×106 HeLa cells were either mock-treated,
treated with, 1 mM NaOV for 2 h and then were infected with
AAV2-adiponectin vectors at 104 particles/cell for 2 h at 37 °C. In
some experiments cells were either mock-treated or treated with
4 μM MG132 for 4 h and then were infected with AAV2-adiponectin
vectors at 104 particles/cell for 2 h at 37 °C, which were mock-
incubated or pre-incubated with ATP, EGFR-TPK, or both. For
immunoprecipitations, cells were treated with 0.01% trypsin and
washed extensively with PBS to remove any adsorbed and
unadsorbed virus particles after treatment or at 4 h post-infection
and then resuspended in 1 ml hypotonic buffer (20 mM HEPES pH
7.5, 5 mM KCl, 0.5 mM MgCl2) containing 1 mM DTT, 10 mM NaF,
2 mM Na3VO4, 0.5 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin
and 10 μg/ml. WCLs were prepared by homogenization in a tight-
ﬁtting Duall tissue grinder until about 95% cell lysis was achieved as
monitored by trypan blue dye exclusion assay. WCLs were cleared of
non-speciﬁc binding by incubation with 0.25 mg of normal mouse
IgG together with 20 μl of protein G plus-agarose beads for 60 min
at 4 °C in an orbital shaker. After preclearing, 2 μg of capsid
antibody against intact AAV2 particles (A20) (mouse IgG3) or 2 μg of
normal mouse IgG (as a negative control) was added and incubated
at 4 °C for 1 h, followed by precipitation with protein G-agarosebeads at 4 °C for 12 h in a shaker. Pellets were collected by
centrifugation at 2500 rpm for 5 min at 4 °C and washed four times
with PBS. After the ﬁnal wash, supernatants were aspirated and
discarded, and pellets were resuspended in equal volume of 2× SDS
sample buffer. Twenty μl of resuspended pellet solutions were used
for Western blotting with HRP-conjugated anti-Ub antibody as
described below.
Western blot analyses
Western blotting was performed as described previously (Zhao
et al., 2006; Zhong et al., 2004d; Zhong and Su, 2002). For in vitro
phosphorylation assays, the reaction mixtures were separated by 10%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
Immobilon-P membranes (Millipore, Bedford, MA). Membranes were
blocked at 4 °C for 12 h with 5% nonfat milk in 1× Tris-buffered saline
(TBS, 20mMTris–HCl, pH 7.5,150mMNaCl). Membranes were treated
with monoclonal anti-p-Tyr antibody (1:300 dilution) or monoclonal
anti-AAV2 capsid proteins antibody followed by horseradish perox-
idase-conjugated anti-mouse IgG2b or anti-mouse IgG1 (1:10,000
dilution). For immunoprecipitations, resuspended pellet solutions
were boiled for 2–3 min and 20 μl of samples were used for SDS-PAGE.
After blocking at 4 °C for 12 h with 5% nonfat milk in 1× Tris-buffered
saline, membranes were treated with monoclonal HRP-conjugated
anti-Ub antibody (1:2000 dilution). Immuno-reactive bands were
visualized using chemiluminescence (ECL-plus, Amersham Pharmacia
Biotech, Piscataway, NJ).
Isolation of nuclear and cytoplasmic fractions from HeLa cells
Nuclear and cytoplasmic fractions from HeLa cells were isolated as
described previously (Zhong et al., 2004c, 2007). Brieﬂy, mock-
infected or recombinant ssAAV2-lacZ vector-infected cells were
washed twice with PBS at 18 h post-infection, treated with 0.01%
trypsin and washed extensively with PBS to remove any adsorbed and
unadsorbed virus particles. Cell pellets were gently resuspended in
200 μl hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM DTT, 0.5 mM PMSF) and incubated on ice for 5 min, after
which 10 μl 10% NP-40 was added, and observed under a light
microscope. Samples were mixed gently and centrifuged for 5 min at
500 rpm at 4 °C. Supernatants (cytoplasmic fraction) were decanted
and stored on ice. Pellets (nuclear fractions) were washed twice with
1 ml hypotonic buffer and stored on ice. The purity of each fraction
was determined to be N95%, as measured by the absence of acid
phosphatase activity (nuclear fractions) and absence of histone H3
(cytoplasmic fractions) as described previously (Hansen et al., 2000;
Zhong et al., 2004c).
Southern blot analysis for AAV2 trafﬁcking
Low-Mr DNA samples from nuclear and cytoplasmic fractions
were isolated and electrophoresed on 1% agarose gels or 1%
alkaline-agarose gels followed by Southern blot hybridization
using a 32P-labeled lacZ-speciﬁc DNA probe as described previously
(Hansen et al., 2000; Zhong et al., 2004c). Densitometric scanning of
autoradiographs for the quantitation was evaluated with ImageJ
analysis software (NIH, Bethesda, MD).
Recombinant AAV2 vector transduction assays
Approximately 1×105 HeLa cells were plated in each well in 12-
well plates and incubated at 37 °C for 12 h. Cells were washed once
with IMDM and then infected at 37 °C for 2 h with recombinant AAV2
vectors as described previously (Qing et al., 2001; Zhong et al., 2004a,
2004d). Cells were incubated in complete IMDM containing 10% NCS
and 1% antibiotics for 48 h. The transduction efﬁciency was measured
201L. Zhong et al. / Virology 381 (2008) 194–202by EGFP imaging using a Leica DM IRB/E ﬂuorescence microscope
(Leica Microsystems Wetzlar GmbH, Wetzlar, Germany). Images from
three to ﬁve visual ﬁelds of mock-infected and vector-infected HeLa
cells at 48 h post-infection were analyzed quantitatively by ImageJ
analysis software (NIH, Bethesda, MD, USA). Transgene expressionwas
assessed as total area of green ﬂuorescence (pixel2) per visual ﬁeld
(mean±SD). Analysis of variance (ANOVA) was used to compare
between test results and the control and they were determined to be
statistically signiﬁcant.
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